About: Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Background: Increased activity of intestinal alkaline phosphatase (AP) occurs locally in patients with ulcerative colitis (UC), aimed at repairing inflammatory tissue damage. We evaluated the safety and preliminary efficacy of exogenous AP administered to patients with UC in an open-label, first-in-patient exploratory trial, conducted in the Internal Medicine and Gastroenterology hospital departments in the Czech Republic and Italy. Methods: Twenty-one patients were enrolled (13 females), age 23-54 years, with steroid- and/or immunosuppressant-refractory, moderate/severe UC (Mayo score 6-11). Oral AP enzyme 30,000 U was administered daily for 7 days, intraduodenally. Efficacy outcomes were changes in Mayo score at Day 21 posttreatment; changes in Modified Truelove Witts Severity index (MTWSI) at Days 21, 63; C-reactive protein and stool calprotectin levels at Days 7, 21, 63. Safety evaluations were adverse events and laboratory abnormalities reported up to Day 63 posttreatment. Results: No clinicall Background: Increased activity of intestinal alkaline phosphatase (AP) occurs locally in patients with ulcerative colitis (UC), aimed at repairing inflammatory tissue damage. We evaluated the safety and preliminary efficacy of exogenous AP administered to patients with UC in an open-label, first-in-patient exploratory trial, conducted in the Internal Medicine and Gastroenterology hospital departments in the Czech Republic and Italy. Methods: Twenty-one patients were enrolled (13 females), age 23-54 years, with steroid- and/or immunosuppressant-refractory, moderate/severe UC (Mayo score 6-11). Oral AP enzyme 30,000 U was administered daily for 7 days, intraduodenally. Efficacy outcomes were changes in Mayo score at Day 21 posttreatment; changes in Modified Truelove Witts Severity index (MTWSI) at Days 21, 63; C-reactive protein and stool calprotectin levels at Days 7, 21, 63. Safety evaluations were adverse events and laboratory abnormalities reported up to Day 63 posttreatment. Results: No clinicall (en)
Title	Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis (en)
skos:prefLabel	Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis (en)
skos:notation	RIV/00023001:_____/10:00002373!RIV11-MZ0-00023001
http://linked.open...avai/riv/aktivita	N V
http://linked.open...avai/riv/aktivity	N, V
http://linked.open...iv/cisloPeriodika	7
http://linked.open...vai/riv/dodaniDat	2011
http://linked.open...aciTvurceVysledku	Drastich, Pavel
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Institut klinické a experimentální medicíny
http://linked.open...dnocenehoVysledku	258199
http://linked.open...ai/riv/idVysledku	RIV/00023001:_____/10:00002373
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	alkaline phosphatase; ulcerative colitis; clinical trial; inflammatory bowel disease (en)
http://linked.open.../riv/klicoveSlovo	clinical trial ulcerative colitis alkaline phosphatase inflammatory bowel disease
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[0576BD257E1F]
http://linked.open...i/riv/nazevZdroje	Inflammatory bowel diseases
http://linked.open...in/vavai/riv/obor	FE
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	9 (xsd:int)
http://linked.open...UplatneniVysledku	2010
http://linked.open...v/svazekPeriodika	16
http://linked.open...iv/tvurceVysledku	Drastich, Pavel Konečný, M. Urban, O. Gionchetti, P. Lukáš, M. Bortlík, M. Duricova, D. Bulitta, M. Cantoni, F.
http://linked.open...ain/vavai/riv/wos	000279718800015
issn	1078-0998
number of pages	7 (xsd:int)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software